AB-101 is a cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers
Granted Fast Track designation by U.S. FDA for the treatment of relapsed/refractory non-Hodgkin lymphoma of B cell origin, in combination with rituximab.
